Clinical Trial to Evaluate the Safety and Efficacy of NTCB01-1 in Patients Who Require Parenteral Nutrition

Exclusion Criteria

• •Patients are expected difficult to survive more than 3 days
• •Patients BMI is over 30 kg/m2
• •Patients having hypersensitivity to any peanut-, fish-, soy-, egg protein, or investigational drug
• •Patients with difficult peripheral intravenous line
• •Patients judged to be unsuitable for this trial by investigators